Dbv Technologies S.A. | Mid-cap | Healthcare
€2.31
-3.96%
| Dbv Technologies Stock Comparison:
Dbv Technologies vs Abivax SADbv Technologies vs Medincell S.ADbv Technologies vs Valneva SEDbv Technologies vs NanobiotixDbv Technologies vs Inventiva S.ADbv Technologies vs CAC 40 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0
Operating Income -35.0M
Net Income -35.7M
EPS (Diluted) €-0.31

Balance Sheet Metrics

Total Assets 122.2M
Total Liabilities 48.7M
Shareholders Equity 73.5M
Debt to Equity 0.66

Cash Flow Metrics

Operating Cash Flow -34.0M
Free Cash Flow -28.9M

Revenue & Profitability Trend

Dbv Technologies Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i76.1M60.2M75.5M70.3M104.3M
Selling, General & Administrative i20.3M22.9M17.6M21.7M33.3M
Other Operating Expenses i-4.3K-7.0M874.0K1.8M-1.4M
Total Operating Expenses i96.4M76.1M94.0M93.8M136.3M
Operating Income i-99.3M-76.5M-96.6M-99.5M-138.9M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i-----
Interest Expense i----743.4K
Other Non-Operating Income---920.0K-24.2M
Pre-tax Income i-97.0M-72.7M-96.2M-98.2M-163.8M
Income Tax i46.9K7.0K70.0K-381.0K-10.3K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-97.0M-72.7M-96.3M-97.8M-163.8M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-92.9M-67.4M-83.5M-87.2M-101.9M
EPS (Basic) i€-1.17€-0.76€-1.24€-1.78€-2.95
EPS (Diluted) i€-1.17€-0.76€-1.24€-1.78€-2.95
Basic Shares Outstanding i82932826108055996797416805642084655541700
Diluted Shares Outstanding i82932826108055996797416805642084655541700

Income Statement Trend

Dbv Technologies Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i27.6M141.4M209.2M77.3M201.6M
Short-term Investments i-----
Accounts Receivable i-0002.3M
Inventory i----0
Other Current Assets--1.0K1.0K1.0K1.0K
Total Current Assets i37.8M158.9M223.1M114.4M212.9M
Non-Current Assets
Property, Plant & Equipment i25.6M30.1M23.0M28.8M34.1M
Goodwill i34.1K58.0K10.0K22.0K42.1K
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets94.6K6.1M4.1M4.2M28.0M
Total Non-Current Assets i18.1M24.1M23.4M32.3M66.6M
Total Assets i55.9M183.0M246.5M146.7M279.5M
Liabilities
Current Liabilities
Accounts Payable i18.8M23.3M14.5M11.4M20.9M
Short-term Debt i1.3M2.0M3.0M4.8M5.6M
Current Portion of Long-term Debt-----
Other Current Liabilities6.3M11.8M9.8M10.8M22.3M
Total Current Liabilities i26.5M37.3M29.5M31.4M54.1M
Non-Current Liabilities
Long-term Debt i5.4M4.5M1.1M7.1M11.3M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities713.9K934.0K21.4M8.9M3.1M
Total Non-Current Liabilities i6.1M5.5M22.5M16.1M14.4M
Total Liabilities i32.6M42.8M52.1M47.4M68.5M
Equity
Common Stock i9.9M11.0M10.7M6.5M6.7M
Retained Earnings i-244.0M-238.9M-259.6M-258.5M-984.2M
Treasury Stock i1.1M1.3M1.1M1.2M1.2M
Other Equity-----
Total Shareholders Equity i23.3M140.2M194.5M99.3M211.0M
Key Metrics
Total Debt i6.6M6.6M4.2M12.0M16.9M
Working Capital i11.3M121.6M193.6M83.0M158.8M

Balance Sheet Composition

Dbv Technologies Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-97.0M-72.7M-96.3M-97.8M-163.8M
Depreciation & Amortization i-788.0K-14.0M13.2M8.4M10.7M
Stock-Based Compensation i3.9M6.0M5.0M3.1M-1.2M
Working Capital Changes i4.9M953.0K22.3M-22.8M-16.0M
Operating Cash Flow i-89.0M-79.7M-55.8M-108.4M-169.6M
Investing Activities
Capital Expenditures i-2.0M-677.0K-746.0K-306.0K-2.8M
Acquisitions i-----
Investment Purchases i--285.0K-123.0K-119.0K-105.8K
Investment Sales i-154.0K770.0K0-
Investing Cash Flow i-642.3K-808.0K-100.0K-425.0K-2.9M
Financing Activities
Share Repurchases i-40.0K-154.0K---578.1K
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----311.1K
Financing Cash Flow i500.1K6.8M194.1M274.0K153.2M
Free Cash Flow i-91.0M-80.3M-56.4M-109.2M-172.9M
Net Change in Cash i-89.1M-73.8M138.2M-108.6M-19.3M

Cash Flow Trend

Dbv Technologies Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -2.05
Forward P/E -3.33
Price to Book 3.81
Price to Sales 86.41
PEG Ratio 0.23

Profitability Ratios

Profit Margin 0.00%
Operating Margin -2,806.14%
Return on Equity -148.09%
Return on Assets -59.16%

Financial Health

Current Ratio 2.45
Debt to Equity 8.92
Beta 0.43

Per Share Data

EPS (TTM) €-0.96
Book Value per Share €0.63
Revenue per Share €0.04

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
dbv328.3M-2.053.81-148.09%0.00%8.92
Abivax SA 5.6B-25.79-94.87-499.78%0.00%-2.04
Medincell S.A 879.5M--112.65%-66.50%-4.11
Valneva SE 839.7M70.644.44-38.02%-34.15%105.63
Nanobiotix 819.6M-11.81-103.70%0.00%-0.07
Inventiva S.A 742.6M-1.63-21.80172.73%0.00%-14.91

Financial data is updated regularly. All figures are in the company's reporting currency.